Becton, Dickinson and Company $BDX Shares Bought by Deroy & Devereaux Private Investment Counsel Inc.

Deroy & Devereaux Private Investment Counsel Inc. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 16.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 156,143 shares of the medical instruments supplier’s stock after purchasing an additional 22,532 shares during the quarter. Becton, Dickinson and Company comprises approximately 1.5% of Deroy & Devereaux Private Investment Counsel Inc.’s portfolio, making the stock its 26th largest holding. Deroy & Devereaux Private Investment Counsel Inc. owned about 0.05% of Becton, Dickinson and Company worth $26,896,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Mutual Advisors LLC increased its stake in Becton, Dickinson and Company by 32.9% in the second quarter. Mutual Advisors LLC now owns 3,959 shares of the medical instruments supplier’s stock valued at $734,000 after purchasing an additional 980 shares during the period. Twin Tree Management LP increased its stake in Becton, Dickinson and Company by 1,227.5% in the second quarter. Twin Tree Management LP now owns 22,568 shares of the medical instruments supplier’s stock valued at $3,887,000 after purchasing an additional 20,868 shares during the period. Cypress Wealth Services LLC increased its stake in Becton, Dickinson and Company by 18.9% in the second quarter. Cypress Wealth Services LLC now owns 3,592 shares of the medical instruments supplier’s stock valued at $619,000 after purchasing an additional 570 shares during the period. Courier Capital LLC increased its stake in Becton, Dickinson and Company by 3.2% in the second quarter. Courier Capital LLC now owns 5,355 shares of the medical instruments supplier’s stock valued at $922,000 after purchasing an additional 166 shares during the period. Finally, Equitable Trust Co. increased its stake in Becton, Dickinson and Company by 23.5% in the second quarter. Equitable Trust Co. now owns 10,946 shares of the medical instruments supplier’s stock valued at $1,885,000 after purchasing an additional 2,081 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock worth $562,036 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Trading Up 0.9%

Shares of BDX opened at $188.31 on Wednesday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average is $190.46 and its two-hundred day moving average is $185.47. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm has a market capitalization of $53.97 billion, a P/E ratio of 33.87, a PEG ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion for the quarter. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.